ChemiCare has closed a €2.5 million seed round subscribed by CDP Venture Capital SGR, Bio4Dreams and Bridge4Pharma.
It is an SME incubated and owned by Bio4Dreams, specializing in the development of drugs that modulate Store-Operated Calcium Entry (SOCE), a key mechanism in the functioning of immune cells.
The goal is to complete preclinical studies and accelerate the path toward clinical trial approval for CIC-39.
CIC-39 is a drug candidate for Duchenne muscular dystrophy and autoimmune diseases such as multiple sclerosis and lupus, with orphan drug designation from the EMA and FDA.
ChemiCare has been part of the Bio4Dreams network for over three years, making this achievement one that also highlights the work of the incubator.
“It is extremely gratifying to see years of work translate into real opportunities to address an unmet medical need.”
Beatrice Riva, Co-founder and CEO of ChemiCare
"This is the beginning of a promising new chapter that we are proud to embark on together."
Elisabetta Borello, Co-Founder, VP Strategy & External Relations at Bio4Dreams
👉 Read the full news article
